Astria Therapeutics (ATXS) Peer Comparison

$12.48

$-0.33 (-2.58%)

As on 16-Jan-2026 12:34EDT

Market cap

$718 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

5.2

Div. Yield

0 %

Edit

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Market cap ($ Mln)	718	20,026
Revenue ($ Mln)	1	3,247
Net Profit ($ Mln)	-124.03	-207.95
Net Margin (%)	-17,567.99	-6.40
RoE (%)	-47.47	-8.66
Price to Earnings	--	--
Price-To-Book	5.21	8.34

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Operating Revenue	0.71	3,246.99
Cost of Revenue	0.00	984.24
Gross Profit	--	1,918.67
Operating Expenses	137.22	2,463.14
Operating Profit (EBIT)	-136.51	-200.38
Other Income	0.00	0.00
Profit before Tax	-124.03	-203.89
Provision for Tax	0.04	4.06
Profit after Tax (Net Income)	-124.03	-207.95
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Shareholder's Funds	233.25	2,401.05
Minority Interest	0.00	0.00
Non-Current Liabilities	15.10	2,818.43
Current Liabilities	23.52	641.15
Total Liabilities	342.36	5,928.14

Assets ($ Mln)

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Non-Current Assets	18.32	4,118.97
Current Assets	253.55	1,429.57
Total Assets	342.36	5,928.14
Total Debt*	4.46	2,522.70
Net Current Assets	230.03	914.70

Cashflow ($ Mln)

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Cash From Operating Activities	-81.21	210.54
Cash Flow from Investing Activities	-191.86	-442.16
Cash from Financing Activities	157.20	231.87
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
ROCE (%)	-33.19	-18.95
ROE (%)	-47.47	-8.54
ROA (%)	-36.87	-3.19
EBIT Margin (%)	-14,498.97	-5.51
Net Margin (%)	-17,567.99	-6.40
Cash Profit Margin (%)	--	0.00

Growth Ratios

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Revenue Growth (%)	--	17.69
EBIT Growth (%)	-1.38	82.40
Net Profit Growth (%)	-23.98	79.79
EPS Growth (%)	-2.24	80.14
Book Value Growth (%)	-33.52	-2.38

Valuation Ratios

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Price / Earnings	-5.35	-10.12
Price / Book Value	1.58	4.33
Dividend Yield (%)	--	--
EV/EBITDA	-1.63	-15.37
Market Cap ($ Cr)	--	--

Solvency Ratios

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Debt to Equity	0.00	0.97
Short term debt to equity ratio	0.01	0.02
Current Ratio	10.78	2.23
Quick Ratio	10.78	1.97
Interest Coverage	--	-4.56

Operating Efficiency Ratios

	Astria Therapeutics (ATXS)	EXACT Sciences Corporation (EXAS)
Debtors to sales (%)	2,442.35	9.20
Asset Turnover	0.00	0.50
Receivable days	--	29.96
Inventory Days	--	63.00
Payable days	--	36.60
Cash Conversion Cycle	--	56.36

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly